| Epidermal growth factor receptor tyrosine kinase inhibitors are the standard first-line treatment options for patients with advanced non-small cell lung cancer with epidermal growth factor receptor mutations.EGFR-TKIs resistance seriously affects the prognosis of patients, and the exploration of the mechanism of EGFR-TKIs resistance and the subsequent treatment are the difficulties and focuses of the current research. In recent years, immune checkpoint inhibitors have demonstrated significant advantages in the treatment of EGFR-TKIs-resistant advanced NSCLC. This review looks at the current status of EGFR-TKIs-resistant NSCLC in terms of immune-related mechanisms, immune therapy, immune-combination targeting, chemotherapy, anti-angiogenesis, and dual-antibiotic therapy; and predicts the choice of EGFR-tolerant NSCLC based on indicators such as programmed cell death factor ligand 1 expression, tumor mutational load, EGFR mutation We also predicted and selected the superior population after EGFR resistance based on the programmed cell death factor ligand 1 expression, tumor mutation load, EGFR mutation type and metabolites, etc. We elaborated the results with the aim of providing reference for the research and clinical of EGFR-TKIs resistance treatment. |
